BioJapan will take place on October 11-13 2017 in Yokohama, Japan. Mycenax’s business development team will be attending this event to meet partnering opportunities associated with our pipelines, including TuNEX®
, a soluble tumor necrosis receptor (TNFR) fusion protein, can be used for the treatment of inflammatory symptoms by rheumatoid arthritis (RA). Approving letter of NDA from TFDA for TuNEX was received in July 2017, and TuNEX®
is expected to launch by the end of this year. In addition to RA, phase III study of another indication, ankylosing spondylitis, is ongoing in Taiwan.
LusiNEX (Tocilizumab), a biosimilar version of Actemra®
, is the humanized monoclonal antibody IgG1 targeting interleukin-6 receptor (IL-6R). By binding IL-6R, it blocks the inflammatory response and joint erosion. Australian Government Department of Health and
has approved the phase I application (TGA) for LusiNEX in September 2017. In addition, CTA submission in Europe is expected in October 2017. Mycenax is actively looking for licensing partner for the further development.
Booth: C11 (join the booth of Lmed)